Acute myeloid leukemia has more small-cap biotech exposure than almost any other hematologic malignancy right now, largely because it's an area where a modest survival benefit is still clinically meaningful and commercially fundable. Three names worth tracking this quarter — SELLAS Life Sciences (SLS), Actinium Pharmaceuticals (ATNM), and Moleculin Biotech (MBRX) — all sit at different points on the same continuum: a completed or ongoing Phase 2, feeding a pivotal trial that's either near its final analysis or still enrolling toward one.
The clinical stories are genuinely differentiated. The balance sheets are not created equal at all.
The clinical picture
SELLAS is the furthest along. Its lead asset, galinpepimut-S (GPS), a WT1-targeted immunotherapeutic, is in the pivotal Phase 3 REGAL trial as maintenance therapy for AML patients in second complete remission. REGAL is event-driven — it reads out after 80 deaths across the trial population — and as of mid-May 2026 the company had been informed that 78 of 80 required events had occurred. That's about as close to a readout as an event-driven trial gets without an actual data cut.
Actinium already has one completed Phase 3 on the board: the SIERRA trial of Iomab-B, a CD45-targeted radioconjugate used as a conditioning agent before stem cell transplant in relapsed/refractory AML, hit its primary endpoint of durable complete remission (it missed the secondary overall-survival endpoint due to substantial crossover from the control arm). The company's second hematology asset, Actimab-A, a CD33-targeted radiotherapeutic, is designated "Phase 2/3 ready" and is being positioned as a mutation-agnostic combination backbone across AML treatment settings — but it still needs a partner or fresh capital to actually start that trial.
Moleculin is running an adaptive Phase 2B/3 design (the MIRACLE trial) for Annamycin plus cytarabine in relapsed/refractory AML, with Phase 2B data feeding directly into the Phase 3 portion per FDA Project Optimus guidance. As of Q1 2026 the trial had enrolled 45 of a planned 90 subjects, with early blinded results showing a 40% remission rate against a historically weaker cytarabine-alone comparator.
The balance sheets, side by side
This is where the differential actually earns its name. All figures below are pulled directly from each company's Q1 2026 Form 10-Q (period ended March 31, 2026).
| Company | Cash & equiv. | Total assets | Total liabilities | Stockholders' equity |
|---|---|---|---|---|
| SELLAS (SLS) | $107.1M | $114.2M | $6.8M | $107.4M |
| Actinium (ATNM) | $42.1M | $45.4M | $43.1M* | $2.3M |
| Moleculin (MBRX) | $10.3M | $23.4M | $8.2M | $15.2M |
*$35.0M of Actinium's liabilities is non-cash deferred license revenue from a 2022 ex-U.S. licensing deal, not debt requiring cash service — see the note below.
SELLAS is the standout on pure balance-sheet health: essentially debt-free, cash roughly tripled year-over-year on warrant exercises, and a new $150M at-the-market facility sitting unused as a backstop. That matters more than usual here, because a positive REGAL result would put the company on a BLA-filing timeline that requires sustained spending on manufacturing and regulatory work — exactly the kind of runway a thin balance sheet can't support.
Moleculin sits in the middle: enough cash to fund the current enrollment push, but management has been explicit that current cash is not sufficient to fund operations for a full year without additional financing — worth pricing into any position sized around the MIRACLE Phase 3 initiation.
The read
None of this tells you what REGAL, MIRACLE, or a future Actimab-A trial will actually show. Clinical signal and balance sheet health are independent variables — a company can have both, neither, or exactly one. What the financial overlay does is tell you which binary event you're actually underwriting: for SELLAS, it's almost purely the clinical result, since the company can fund the aftermath either way. For Actinium and Moleculin, a positive readout still leaves a financing question that a press release won't answer.
This piece reflects clinical and financial analysis based on public filings and disclosures as of August 2026. It is not investment advice, and Stevenson HemOnc Advisors does not hold, and has not been compensated by, any company named above.